<DOC>
	<DOCNO>NCT00988442</DOCNO>
	<brief_summary>This study test system nurse telephone support see improves adherence antiretroviral therapy ( ART ) at-risk , treatment-experienced people .</brief_summary>
	<brief_title>Telephone Support Improve Adherence Anti-HIV Medications</brief_title>
	<detailed_description>Antiretroviral therapy ( ART ) successful treat HIV people take medication prescribe instructed . However , third patient ART able adhere medication regimen . Therefore , make sure patient stay healthy involves make sure motivate informed importance adhere ART . Nurses deliver intervention motivate inform patient regularly schedule phone call . These call allow nurse check clinic visit , convenient patient , cost efficient . This study test enhance telephone support intervention provide nurse aim improve ART adherence treatment outcome . Participation study last 48 week , follow-up last 72 week . Participants randomly assign receive either care usual enhance telephone support intervention plus care usual . The telephone support intervention involve phone call make weekly first 8 week study every 2 week next 40 week . Nurses make call time place participant choose . During call , nurse provide information , motivational enhancement , problem-solving skill . Study assessment take place study entry 12 , 24 , 48 , 72 week . Assessments measure CD4 cell count , HIV viral load , adherence , illness event . Adherence measure questionnaire electronic pill cap .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Enrollment AIDS Clinical Trials Group ( ACTG ) treatment study approve A5251 parent coenrolling partner study Virologic failure combination antiretroviral therapy ( ART ) , HIV1 genotype conduct soon failure , within 16 week prior entry . HIV1 genotype result must available entry . History prior nonadherence ART past year document either patient selfreport record patient 's medical record Most recent HIV1 RNA value least 400 copies/mL , obtain within 90 day prior study entry measure use FDAapproved test quantify HIV1 RNA Initiating new ART regimen within 3 day randomization two new antiretroviral ( ARV ) medication participant expect susceptible base HIV1 genotype , specify parent coenrolling partner study determine site investigator . The regimen must select participant prior time randomization A5251 . Ability CD4+ cell count plasma HIV1 RNA assay component parent coenrolling partner study per mechanism . Only HIV1 RNA week 48 confirmation virologic failure collect A5251 , unless collect parent coenrolling partner study per exact A5251 specification . No regular access phone . Candidates without phone may elect participate call HIV nurse specialist use 800 number , rather call HIV nurse specialist . Coenrollment another adherence trial , unless approve A5251 study chair Current incarceration Any condition , opinion site investigator , would compromise candidate 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Treatment</keyword>
	<keyword>Adherence Intervention</keyword>
	<keyword>Telephone Intervention</keyword>
	<keyword>treatment experience</keyword>
</DOC>